Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (SToMP-AD): A Pilot Clinical Trial

Medicine and Dentistry

• Age 20%
• Alzheimer's Disease 100%
• Amaurosis 20%
• Analysis 20%
• Brain 40%
• Brain Blood Flow 20%
• Cells 40%
• Cellular Senescence 20%
• Central Nervous System 20%
• Cerebrospinal Fluid 20%
• Clinical Study 40%
• Clinical Trial 80%
• Combination Therapy 40%
• Dasatinib 60%
• Deterioration 20%
• Development 20%
• Drive 20%
• Neuroinflammation 20%
• Older Adult 20%
• Organ Systems 20%
• Pathogenesis 20%
• Phase II Trials 40%
• Placebo 40%
• Protein 20%
• Quercetin 60%
• Senescence 20%
• Tau 20%
• Tau Protein 20%
• Tauopathy 40%
• Therapeutic Procedure 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Alzheimer Disease 100%
• Blindness 20%
• Combination Therapy 20%
• Dasatinib 60%
• Mouse 20%
• Mouse Model 20%
• Nervous System Inflammation 20%
• Pathogenesis 20%
• Preclinical Study 20%
• Protein 20%
• Quercetin 60%
• Tau Protein 20%
• Tauopathy 40%